321. THE PREVALENCE OF MYOCARDIAL SCAR IN PATIENTS NO PRIOR HISTORY OF CARDIAC DISEASE DETECTED BY DELAYED-ENHANCEMENT CARDIAC MAGNETIC RESONANCE
Simon Greulich, MD,¹ Igor Klem, MD,¹ John F. Heitner, MD,² Holger Vogelsberg, MD,¹ Srivani Ambati, MD,³ Martina Mangin, MD,¹ Udo Sechtem, MD¹. ¹Robert-Bosch-Krankehaus, Stuttgart, Germany, ²New York Methodist Hospital, New York, NY, USA, ³Duke University Medical Center, Durham, NC, USA.
Background: Patients with myocardial scar (scar) are at increased risk for cardiovascular mortality and morbidity. Delayed enhancement cardiac magnetic resonance imaging (DE-CMR) is highly accurate in the detection of scar. The pattern of myocardial scar can be divided into 2 groups: 1. Coronary artery disease (CAD) based on location, ie extending from subendocardium to subepicardium; and 2. Non-CAD based on mid-myocardial or epicardial location. The prevelance of these patterns of scar in patients with no prior history of infarction or CAD is unknown.
Purpose: To assess the prevalence of scar (both CAD and Non-CAD) by DE-CMR in patients with clinically suspected CAD and no previous cardiac disease.
Methods: We prospectively enrolled 42 consecutive patients (pts) without a prior history of cardiac disease including myocardial infarction who were referred for elective coronary angiography (CA) based on clinical suspicion of CAD. DE-CMR was performed in all patients within 24 hrs of CA. DE-CMR images were scored visually, blinded to patient identity, using a 17-segment model. The presence of silent MI by DE-CMR was defined as the presence of hyperenhanced myocardium in a pattern typical of CAD. Non-CAD pattern of hyperenhancement was defined as either midmyocardial or epicardial HE representing primary myocardial disease. Patients were considered positive for CAD if there was ≥ 70% coronary stenosis on CA.
Results: The prevalence of CAD by CA was 38% (16 pts). DE-CMR showed evidence of HE in 9 pts (21%). Four (44%) patients had a HE pattern consistent with CAD, and 5 pts. (56%) had Non-CAD type of HE. The mean silent MI size was 9.4% of total LV mass, the mean size of scar in the Non-CAD group was 1% of total LV mass. Of the 4 pts. with evidence of silent MI by DE-CMR, three had significant stenosis on CA, and one pt. had non-obstructive disease on CA. Among the 5 pts. with evidence of Non-CAD type of scar, 4 had no CAD on CA, one pt. with HE in the midmyocardial basal septum (0.8% of LV mass) had evidence of obstructive CAD (posterior descending artery) on CA.
Conclusion: There is a high prevalence of scar in patients with clinically suspected CAD but without previously known cardiac disease. DE-CMR has additive diagnostic value for the evaluation of patients with clinical suspicion of CAD.
322. CARDIOVASCULAR SAFETY OF EVP 1001-1 (SEEMORE™), AN INTRACELLULAR AGENT FOR MAGNETIC RESONANCE IMAGING OF THE ISCHEMIC HEART
Peter R. Seoane, PhD, Phillip P. Harnish, PhD. Eagle Vision Pharmaceutical Corp., Exton, PA, USA.
Introduction: Manganese (Mn) has demonstrated potential utility for imaging of the heart from the early days of magnetic resonance imaging. Mn has been shown to distribute rapidly from the blood to myocardium, providing a persistent pattern of enhancement that reflects local perfusion at the time of intracellular uptake. Unfortunately, Mn activity at calcium channels depresses the heart and relaxes blood vessels at doses and rates of administration relevant for imaging. This results in acute decreases in blood pressure, electrical disturbances such as prolonged P-R and Q-T intervals and ventricular arrhythmias. One may improve the cardiac safety of Mn via chelation while sacrificing two key advantages of Mn, rapid tissue uptake and high relaxivity. These factors significantly limit the utility of chelated Mn for imaging the ischemic heart. Through formulation with calcium, EVP 1001-1 mitigates the undesired cardiovascular effects associated with Mn while retaining the kinetic and magnetic properties that enable imaging of the ischemic heart.
Purpose: To evaluate the cardiovascular safety of EVP 1001-1 administered to beagle dogs at rest and under peak pharmacologic stress.
Methods: Groups of three anesthetized beagle dogs were dosed with EVP 1001-1 (120 μ mol/kg IV over one minute) at rest, at peak dipyridamole stress (142 μ mol/kg/min IV for 4 minutes) and at peak dobutamine stress (40 μ g/kg/min IV for 20 minutes). Blood pressure, heart rate and electrocardiogram (ECG) were continuously monitored from induction of anesthesia through up to one hour following administration of EVP 1001-1. ECG recordings (12 Lead) were obtained and P-R, R-R and Q-T intervals measured at predetermined timepoints prior to stressor administration, during stress induction and for up to one hour following EVP 1001-1 administration. QTc was derived from Q-T and R-R measurements using Fridericias's correction.
Results: When animals were dosed with EVP 1001-1 at rest, a small increase in mean arterial blood pressure was noted that resolved within minutes of administration. The animal's heart rate was not affected and no significant changes were noted on ECG. In animals that were underwent maximal stress with either dipryridamole or dobutamine, EVP 1001-1 did not exacerbate the hemodynamic stress, alter ECG or result in cardiac rhythm changes. Thus the No Observable Adverse Event Level (NOAEL) for EVP 1001-1 is greater than 120 μ mol/kg, or more than 12 times the anticipated maximum clinical dose.
Conclusions: Cardiac MRI with EVP 1001-1 may be accomplished without the cardiac depression or ECG changes typically associated with Mn, even when given under peak pharmacologic stress. Previous studies have shown that the magnetic and pharmacokinetic properties of EVP 1001-1 are consistent with the requirements for steady state imaging of the ischemic heart. Thus, EVP 1001-1 may be safely administered under exercise or pharmacologic stress away from the magnet, with full cardiac monitoring. Imaging of the stress induced pattern of enhancement, which evolves shortly after administration of EVP 1001-1 and persists for more than 90 minutes, may be performed once the patient has returned to the resting condition. Imaging of the perfusion deficit may be performed as desired during this period without the need for additional stress or doses of EVP 1001-1. Studies in patients are currently underway.
Acknowledgment: This work was supported in part by the National Heart Lung and Blood Institute/NIH, Grant # R44HL63518.
323. CLINICAL SAFETY EVALUATION OF CARDIAC MRI EARLY AFTER CORONARY STENT IMPLANTATION IN ACUTE MYOCARDIAL INFARCTION PATIENTS
Paula Tejedor,¹ Alberto San Román,² Itziar Gómez,² José Sierra,³ Juan Manuel Durán,¹ Francisco Fernández-Avilés.²¹Hospital General Yagüe, Burgos, Spain, ²Hospital Clínico Universitario, Valladolid, Spain, ³Centro Diagnóstico Valladolid, Valladolid, Spain.
Introduction: MRI provides helpful information in patients in the inmediate post-stent PCI (percutaneous coronary intervention) period. However, current “information for use guidelines” recommend to wait at least 8 weeks for the MRI to be safe, because of theoretical concerns of stent dislodgment when exposed under a magnetic field. Most clinicians perform cardiac MRI before 8 weeks, although information on safety is lacking.
Purpose: To determine whether to perform a cardiac MRI in the first 2 weeks after stent-PCI in patients with the diagnosis of AMI is a safe procedure.
Methods: We retrospectively study 409 postAMI patients. Mean age was 62 ± 11, 85% were males. 43% of all the patients were treated by primary PCI (percuataneous coronary intervention) and 76% by facilitated PCI (thrombolysis followed by PCI within 24 hours). Cardiac MRI was performed in 86 patients (group 1, n = 86) according to physician's criteria an average of 14 ± 11 days after the stent implantation. MRI was not performed in group 2(n = 312). All MRI examinations were performed in a 1.5 Tesla scan. Cine-MRI images were obtained using an ultra-fast gradient-echo sequence (FIESTA™, General Electric). Safety outcomes included occurrence of stent thrombosis, myocardial infarction, target vessel revascularization and rehospitalization during index hospitalization and at 6 and 12 months after the AMI.
Results: Baseline and cardiovascular risk factors were not different in both groups. Reperfusion therapy was similar in both groups of patients (). Infarct size determined by quantification of cardiac markers was also quite similar between the two groups. Baseline angiographic mean ejection fraction (EF) was slightly inferior in group 1 (EF = 51 ± 11%) than in group 2 (EF = 55 ± 10, p < 0.008). The vast majority of the implanted stents were 316 L stainless steel in both groups of patients. There was no significant difference in the percentage of patients receiving double antiplatelet therapy (aspirine plus clopidogrel) for at least one month after the stent implantation. No clinical complication was described in the post-inmediate MRI procedure. During index hospitalization, 3 acute stent thrombosis were registered, all of them in group 2 (no CMR). At 12 months, MACE (including death, reinfarction, rehospitalization and revascularization) was 14% in group 1 and 15.6% in group 2 (p = 0.7) ().
Friday Posters
All authors
DOI
http://dx.doi.org/10.1080/10976640500479011
Published online
13 July 2009
Table 1
CSVDisplay Table
Conclusions: Cardiac MRI performed within 2 weeks of stent-PCI in the postAMI setting appears to be a safe procedure, with a very low risk of MACE. Delaying MRI in the immediate post stent implantation period does not appear to be necessary.
324. MICROVASCULAR OBSTRUCTION IN AN EXPERIMENTAL REPERFUSED ACUTE MYOCARDIAL INFARCTION AT THE VERY EARLY STAGE: EVALUATION USING A MODIFIED T1 PREP LOOK-LOCKER SEQUENCE
Yuesong Yang, MD, PhD, Warren D. Foltz, PhD, John Graham, MD, Jay S. Detsky, BSc, Alexander J. Dick, MD, Graham A. Wright, PhD. Sunnybrook and Women's College Health Sciences Centre, Toronto, ON, Canada.
Introduction: The concept of microvascular obstruction (MO) or the “no-reflow” phenomenon in the infarcted myocardium was proposed decades ago using a canine model. However, the linkage between the MO and unfavorable clinical prognosis has been established only in recent years using TIMI flow, myocardial contrast echocardiography and MRI. Delayed enhanced MRI (DE-MRI) has been widely used for myocardial viability determination. The MO in acute myocardial infarctions (AMI) has been detected as hypoenhanced regions. A noninvasive MRI technique with positive enhancement of MO would be preferred.
Purpose: To investigate a modified T1 prep Look-Locker sequence before and during a Gd-DTPA infusion for evaluation of MO in a porcine model of reperfused AMI.
Methods: In seven Yorkshire pigs (22–28 kg) a reperfused AMI was produced under X-ray guidance using a 90-minute percutaneous balloon occlusion of the distal LAD, followed by reperfusion. MRI studies were performed on a GE 1.5T Signa Excite system. All pigs underwent a baseline MRI examination including a SSFP functional study and T1 mapping. The T1 map uses a modified Look-Locker sequence acquiring a set of 8 spiral images, corresponding to the differences between signals in a train of 20-deg excitations at intervals of 120 ms, obtained with and without a preceding inversion at the same cardiac phase. The signal difference isolates the T1 contribution from the approach to steady-state in the small-tip train, so that longer T1 values yield bright signal at later points (effectively longer TI). After the intervention, SSFP and T1 mapping sequences were repeated in the same location. First pass myocardial perfusion (FPMP) was obtained immediately after a Gd-DTPA bolus injection (0.2 mmol/kg) followed by a continuous intravenous drip of Gd-DTPA. DE-MRI was performed 30 minutes post-injection and T1 mapping was applied 45 minutes post-injection. Pigs were sacrificed for TTC staining and histology. SSFP LV function, FPMP and DE-MRI analysis were conducted using Mass Plus software (Medis). T1 change was calculated from the MO, DE-MRI hyperenhanced (DHE), control segments and LV with the following formula: [(T1 at baseline—T1 at steady state post Gd-DTPA)/T1 at baseline] using manually drawn regions-of-interest and custom or commercial fitting algorithms (Xcinema, Stanford; Functool 2, GE).
Results: MO was seen in six of seven pigs. MO was defined as the persistent hypoenhanced area in the infarcted myocardium in FPMP and DE-MRI (). Upon the modified Look-Locker technique post-contrast, MO was identified as bright regions in later difference images while the surrounding DHE regions appeared dark (). shows the typical signals from MO, DHE and control regions in difference images across the small tip train. MO areas calculated from the DE-MRI (1.46 ± 0.84 cm²) and T1 images (1.54 ± 0.91 cm²) in the same location were comparable with a trend toward greater area in the T1 images although no statistical significance was reached (p = 0.20, paired t-test). T1 reduction (%) in MO regions (23.5 ± 21.8) was small compared to measurements from the control segments (38.2 ± 7.3, p = 0.13), DHE regions (72.8 ± 14.5, p = 0.0004) and LV (83.5 ± 10.9, p = 0.005) using a paired t-test. Pre-contrast T1 values across the myocardial segments were the same. All pigs had an AMI demonstrated by TTC staining and histology and occluded microvessels were seen in MO ().
Friday Posters
All authors
DOI
http://dx.doi.org/10.1080/10976640500479011
Published online
13 July 2009
FIG. 1. a. DE-MRI: MO as hypo-enhanced region (TI = 250 ms). b. One T1 prep difference image (post-Gd, TI = 606 ms): MO was positive enhanced area. c. T1 map: ROI 1: MO, ROI 2: DHE, ROI 3: Control region. d. Normalized signal intensity changes over eight data points. e. TTC staining. f. Histology (HE statining): necerosis and hemorrhage present. A small arteriole totally occluded by disrupted red blood cells, platelet and fibrin was observed in MO region.
PowerPoint slideOriginal jpg (17.00KB)Display full size
FIG. 1. a. DE-MRI: MO as hypo-enhanced region (TI = 250 ms). b. One T1 prep difference image (post-Gd, TI = 606 ms): MO was positive enhanced area. c. T1 map: ROI 1: MO, ROI 2: DHE, ROI 3: Control region. d. Normalized signal intensity changes over eight data points. e. TTC staining. f. Histology (HE statining): necerosis and hemorrhage present. A small arteriole totally occluded by disrupted red blood cells, platelet and fibrin was observed in MO region.
Friday Posters
All authors
DOI
http://dx.doi.org/10.1080/10976640500479011
Published online
13 July 2009
FIG. 1.
PowerPoint slideOriginal jpg (13.00KB)Display full size
FIG. 1.
Conclusions: MO at early stages of reperfused AMI can be identified as a bright area on images from a modified T1 prep Look-Locker sequence post-contrast. Observations suggest reduced Gd-DTPA distribution volume in MO relative to both control and DHE regions. Quantitative results yield greater specificity while positive contrast may help identify even partial volumes of MO.